Pulmonary artery hypertension etiopathogenesis, classification,diagnosis, management Make 10 mark answer for dnb medicine exam
Reading File
Finding Sources
Searching PubMed
pulmonary arterial hypertension
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Searching Content
"^#" in /textbooks/9781265977061/9781265977061_block31.md
Finding Sources
Now I have the full section map. Let me read diagnosis, classification, and treatment sections in detail.
Reading File
Reading File
Reading File
Reading File
Pulmonary Arterial Hypertension (PAH) — DNB Medicine (10 Marks)
1. Definition
Pulmonary hypertension (PH) is defined hemodynamically as a mean pulmonary artery pressure (mPAP) >20 mm Hg at rest on right heart catheterization (RHC) (revised 6th World Symposium on Pulmonary Hypertension, 2018). PAH (precapillary PH) additionally requires:
- Pulmonary artery wedge pressure (PAWP) ≤15 mm Hg
- Pulmonary vascular resistance (PVR) >2-3 Wood units (WU)
This distinguishes PAH from post-capillary PH (PAWP >15 mm Hg, e.g., left heart disease), where PVR is low and the process is passive congestion rather than arteriolar remodeling - Braunwald's Heart Disease; Harrison's Principles of Internal Medicine, 22E.
2. Etiopathogenesis
Pathobiology: In PAH, endothelial dysfunction triggers an imbalance between vasodilator/antiproliferative mediators (nitric oxide, prostacyclin) and vasoconstrictor/proliferative mediators (endothelin-1, thromboxane A2). This produces:
- Vasoconstriction of pulmonary arterioles
- Plexogenic and fibrotic remodeling — intimal proliferation, medial hypertrophy, and adventitial thickening, with plexiform lesions in severe disease
- In-situ thrombosis due to a pro-thrombotic endothelial phenotype
- Genetic susceptibility: BMPR2 mutations (most common in heritable PAH), also ALK1, ENG, SMAD9, KCNK3, TBX4
Pathophysiology: Progressive rise in PVR increases right ventricular (RV) afterload → RV hypertrophy → RV dilatation and failure → decreased cardiac output → tricuspid regurgitation, systemic venous congestion, and death from RV failure (not left heart failure).
3. Classification (6th WSPH 2018, retained in ESC/ERS 2022 guidelines)
| Group | Category | Examples |
|---|---|---|
| 1 | Pulmonary arterial hypertension (PAH) | Idiopathic, heritable, drug/toxin-induced (e.g., fenfluramines), associated with connective tissue disease (especially systemic sclerosis), HIV, portal hypertension, congenital heart disease, schistosomiasis; PAH with venous/capillary involvement (PVOD/PCH); persistent PH of newborn |
| 2 | PH due to left heart disease | HFpEF, HFrEF, valvular disease (e.g., mitral stenosis), congenital/acquired left heart conditions |
| 3 | PH due to lung disease/hypoxia | COPD, ILD, mixed restrictive-obstructive disease, sleep-disordered breathing, high-altitude hypoxia |
| 4 | PH due to pulmonary artery obstruction | Chronic thromboembolic PH (CTEPH), other PA obstructions |
| 5 | PH with unclear/multifactorial mechanisms | Hematologic (sickle cell disease), systemic disorders (sarcoidosis), metabolic disorders, chronic kidney disease |
This system replaces the older Dana Point classification and is essential for guiding treatment, since only Group 1 (and select Group 4) responds to PAH-specific vasodilator therapy.
4. Clinical Features
- Progressive exertional dyspnea and fatigue (most common, often insidious)
- Exertional chest pain, presyncope/syncope (advanced disease, low fixed cardiac output)
- Signs of RV failure: raised JVP, hepatomegaly, ascites, pedal edema
- Examination: loud/palpable P2, RV heave, right-sided S3/S4, pansystolic tricuspid regurgitation murmur
- Clues to underlying cause: sclerodactyly/telangiectasia (scleroderma), clubbing (chronic lung disease), signs of liver disease (portopulmonary HTN)
5. Diagnosis
Stepwise approach (screen → confirm etiology → assess severity):
- ECG — RV hypertrophy/strain, right axis deviation, P-pulmonale
- Chest X-ray — enlarged pulmonary arteries, RV enlargement, oligemic lung fields (pruning)
- Echocardiography (with bubble study) — key screening test; estimates PA systolic pressure, assesses RV size/function, detects left heart disease, valvulopathy, or intracardiac shunt
- Pulmonary function tests + CT chest — exclude parenchymal lung disease (Group 3)
- V/Q scan or CT pulmonary angiography — screen for CTEPH (Group 4)
- Right heart catheterization (RHC) — gold standard; confirms mPAP, PAWP, PVR, cardiac output; vasoreactivity testing (with inhaled NO/adenosine) identifies acute responders suitable for high-dose calcium channel blockers
- Additional work-up for etiology: ANA/autoantibody panel (connective tissue disease), HIV serology, liver function/ultrasound (portal hypertension), 6-minute walk test, BNP/NT-proBNP, cardiopulmonary exercise testing for risk stratification
- Risk stratification (WHO functional class, 6-MWD, BNP, hemodynamics) guides treatment intensity - target: low-risk profile (1-year mortality <5%)
6. Management
A. General/Supportive measures
- Diuretics (± mineralocorticoid receptor antagonists) for RV volume overload
- Supplemental oxygen if hypoxemic
- Anticoagulation (selected idiopathic PAH, CTEPH)
- Avoid pregnancy (high mortality); supervised exercise training; low-sodium diet; vaccination
- Treat underlying cause in Groups 2-5 (e.g., optimize left heart disease, treat lung disease, CTEPH surgery)
B. PAH-specific pharmacotherapy (targets 3 pathways):
| Pathway | Drug class | Examples |
|---|---|---|
| Nitric oxide | PDE5 inhibitors / sGC stimulator | Sildenafil, tadalafil / Riociguat |
| Endothelin | Endothelin receptor antagonists (ERA) | Bosentan, ambrisentan, macitentan |
| Prostacyclin | Prostanoids / IP receptor agonist | Epoprostenol (IV), treprostinil, iloprost / Selexipag |
| Activin signaling | Activin receptor fusion protein | Sotatercept (novel, add-on) |
- Acute vasoreactivity responders: high-dose calcium channel blockers (nifedipine, amlodipine, diltiazem)
- Non-responders: upfront combination therapy (ERA + PDE5 inhibitor), supported by the AMBITION trial showing ~50% reduction in clinical worsening versus monotherapy; escalate to triple therapy/parenteral prostanoids in high-risk or progressive disease
C. Interventional/Surgical
- Balloon atrial septostomy — bridge in refractory RV failure
- Pulmonary endarterectomy — curative for operable CTEPH (Group 4)
- Balloon pulmonary angioplasty — inoperable CTEPH
- Lung transplantation — end-stage disease refractory to medical therapy
7. Prognosis
With modern combination therapy, 1-, 3-, and 5-year survival is approximately 82%, 67%, and 58% respectively; early referral to an expert PH center improves outcomes.
Sources: Harrison's Principles of Internal Medicine, 22E, Ch. 294; Braunwald's Heart Disease, 2-Vol Set.
Note on current evidence: Recent systematic reviews (2024-2025) continue to explore PAH therapy effects on oxygenation in PH-lung disease overlap (PMID: 41073131) and novel agents beyond the classic three pathways such as sotatercept (PMID: 37945977) - worth mentioning as "recent advances" for extra marks if time permits in the exam.
This is a shared conversation. Sign in to Orris to start your own chat.